Have a feature idea you'd love to see implemented?
Let us know!
MLTX MoonLake Immunotherapeutics
Price (delayed)
$54.32
Market cap
$3.47B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.27
Enterprise value
$3.1B
moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Highlights
MLTX's equity is up by 15% YoY but it is down by 6% QoQ
The net income has dropped by 57% year-on-year and by 42% since the previous quarter
MLTX's quick ratio is down by 49% year-on-year and by 42% since the previous quarter
Key stats
What are the main financial stats of MLTX
Market
Valuations
Earnings
Shares outstanding
63.91M
Market cap
$3.47B
Enterprise value
$3.1B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$82.45M
EBITDA
-$82.36M
Free cash flow
-$81.09M
Per share
Balance sheet
Liquidity
EPS
-$1.27
Free cash flow per share
-$1.29
Book value per share
$7.64
Revenue per share
$0
TBVPS
$8.24
Total assets
$518.21M
Total liabilities
$22.71M
Debt
$3.38M
Equity
$488.2M
Working capital
$492.24M
Debt to equity
0.01
Current ratio
25.51
Quick ratio
24.72
Net debt/EBITDA
4.52
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-15.4%
Return on equity
-16.2%
Return on invested capital
-67.5%
Return on capital employed
-16.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MLTX stock price
How has the MoonLake Immunotherapeutics stock price performed over time
Intraday
4.74%
1 week
11.24%
1 month
13.17%
1 year
19.89%
YTD
-10.05%
QTD
7.74%
Financial performance
How have MoonLake Immunotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$108.54M
Net income
-$82.74M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 95% year-on-year and by 38% since the previous quarter
The net income has dropped by 57% year-on-year and by 42% since the previous quarter
Growth
What is MoonLake Immunotherapeutics's growth rate over time
Valuation
What is MoonLake Immunotherapeutics stock price valuation
P/E
N/A
P/B
7.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
MoonLake Immunotherapeutics's EPS has decreased by 43% QoQ and by 19% YoY
MLTX's equity is up by 15% YoY but it is down by 6% QoQ
The price to book (P/B) is 11% higher than the last 4 quarters average of 6.4
Efficiency
How efficient is MoonLake Immunotherapeutics business performance
The ROIC has plunged by 56% from the previous quarter but it has grown by 33% YoY
The company's return on assets fell by 41% QoQ but it rose by 16% YoY
The company's return on equity fell by 38% QoQ but it rose by 22% YoY
Dividends
What is MLTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MLTX.
Financial health
How did MoonLake Immunotherapeutics financials performed over time
MLTX's total liabilities has surged by 115% year-on-year and by 53% since the previous quarter
MLTX's quick ratio is down by 49% year-on-year and by 42% since the previous quarter
The debt is 99% smaller than the equity
MLTX's equity is up by 15% YoY but it is down by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.